| Description | BMS453 (BMS-189453), a synthetic retinoid, is a potent and selective agonist of RARβ and a potent testicular toxin. BMS453 inhibits breast cell growth predominantly through the induction of active TGFβ. |
| In vitro | BMS453 (1 μM; 11 hours; 184 and HMEC cells) treatment inhibits the proliferation of normal breast cell growth without significantly inducing apoptosis[2].The RARβ-selective agonist (BMS453), but not RARα- or RARγ-selective agonists (BMS753 and BMS961, respectively), significantly reduced the T47D breast cancer cell migration to levels comparable to inhibition by RA, indicating that RARβ is involved in RA-inhibited cell migration[3]. |
| Synonyms | BMS 453, BMS-189453 |
| molecular weight | 380.48 |
| Molecular formula | C27H24O2 |
| CAS | 166977-43-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 45 mg/mL (118.27 mM) |
| References | 1. J Y Chen, et al. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 1995 Mar 15;14(6):1187-97. 2. L Yang, et al. The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest. Oncogene. 2001 Nov 29;20(55):8025-35. 3. Marina Inés Flamini, Gauna G V , Sottile M L , et al. Retinoic acid reduces migration of human breast cancer cells: role of retinoic acid receptor beta[J]. Journal of Cellular and Molecular Medicine, 2014. |